Compare Adaptive Biotechnologies Corp (ADPT) vs Uber Technologies Inc (UBER) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Uber Technologies Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Uber Technologies Inc trades at $73.42 (market cap $151.31B). The key difference: Uber Technologies Inc is far larger — about 45.4× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Uber Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | UBER | |
|---|---|---|
Market Cap | $3.33B | $151.31B |
Sector | Health | Industrials |
52-Week High | $22.37 | $100.10 |
52-Week Low | $10.24 | $68.61 |
Enterprise Value | $3.19B | $157.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Uber (UBER) trades at $72.42, down 2.7% today, amid a bearish technical signal but strong fundamentals. The stock shows robust revenue growth, with 2025 revenue reaching $52.02 billion, and a net income margin of 15.91%. Recent news highlights strategic moves into autonomous vehicles, including robotaxi pilots in Madrid and Munich, while cost-cutting measures like HR layoffs aim to improve efficiency.
The outlook is mixed: analyst consensus is strongly bullish with a $109.25 price target, but technical indicators and projected 2026 cash flow decline pose risks. Key opportunities include expansion in autonomous driving partnerships; risks involve competitive pressures and execution challenges in new markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
